Archimed to Take Esperion Private in $1.1 Billion Deal
Archimed will acquire Esperion for $3.16 per share, a 58% premium. The deal includes potential sales-based payments and should close in the third quarter.
Xurve View
Insights:
Xurve View
Archimed will acquire ESPERION THERAPEUTICS INC for up to $1.1B, taking the drugmaker private. The $3.16 per share cash offer represents a 58% premium over the last closing price. This buyout provides an immediate exit for shareholders after the stock rose 55% in Friday morning trading.
